Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012

Publisher Name :
Date:26-Dec-2012
No. of pages: 87
Inquire Before Buying

Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia. Chemotherapy Induced Neutropenia – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Neutropenia.
- A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chemotherapy Induced Neutropenia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Chemotherapy Induced Neutropenia 10
Chemotherapy Induced Neutropenia Therapeutics under Development by Companies 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Chemotherapy Induced Neutropenia Therapeutics - Products under Development by Companies 19
Companies Involved in Chemotherapy Induced Neutropenia Therapeutics Development 21
Kyowa Hakko Kirin Co., Ltd. 21
Dong-A Pharmaceutical Co., Ltd. 22
Maxygen, Inc. 23
Teva Pharmaceutical Industries Limited 24
Sandoz Inc. 25
Zosano Pharma, Inc. 26
LTT Bio-Pharma Co., Ltd. 27
Cellerant Therapeutics, Inc. 28
Med Discovery SA 29
Synageva BioPharma Corp. 30
Phage Biotechnology Corporation 31
Inimex Pharmaceuticals, Inc. 32
Bolder Biotechnology, Inc. 33
Welichem Biotech Inc. 34
USV Limited. 35
Pfenex Inc. 36
Eurofarma 37
Chemotherapy Induced Neutropenia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
MAXY-G34 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MDPK-67b - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Slow-Release G-CSF - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Pegylted GCSF - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
filgrastim - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
balugrastim - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IMX-942 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CLT-008 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
filgrastim - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
pegfilgrastim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pegfilgrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
lipegfilgrastim - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
WBI-2100 + [cisplatin] - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
WBI-2100 + [gemcitabine hydrochloride] - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
WBI-2100 + [dacarbazine] - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
WBI-2100 + [paclitaxel] - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
TXA127 + Erythropoietin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
filgrastim - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BBT-015 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BBT-018 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IRX-4310 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
pegfilgrastim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
filgrastim - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
filgrastim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
filgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
F-627 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
F-627 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim Biosimilar - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pegfilgrastim Biosimilar - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Chemotherapy Induced Neutropenia Therapeutics - Drug Profile Updates 75
Chemotherapy Induced Neutropenia Therapeutics - Discontinued Products 79
Chemotherapy Induced Neutropenia Therapeutics - Dormant Products 80
Chemotherapy Induced Neutropenia - Product Development Milestones 81
Featured News & Press Releases 81
Jun 29, 2012: Teva Pharma Provides Clinical Update On Balugrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 81
Jun 29, 2012: Teva Pharma Provides Clinical Update On Lipegfilgrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 81
Oct 10, 2011: Maxygen Announces Final Rejection Of All Claims Of Amgen ‘804 Patent In Inter Partes Reexamination Proceeding 82
May 31, 2011: Teva Announces Data On Granulocyte Colony Stimulating Factor Compounds For Prevention Of Chemotherapy-Induced Neutropenia In Breast Cancer Patients 82
May 31, 2011: Teva To Present Phase II Data Of Granulocyte Colony Stimulating Factor XM22 At ASCO 82
Mar 24, 2011: Telik Announces Preclinical Presentation At 102nd Annual Meeting Of American Association For Cancer Research 83
Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 83
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants 84
Dec 01, 2009: Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia 84
May 08, 2002: Amgen to Acquire Filgrastim and Pegfilgrastim in Europe from Roche 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Chemotherapy Induced Neutropenia, H2 2012 10
Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Development by Companies, H2 2012 (Contd..1) 20
Kyowa Hakko Kirin Co., Ltd., H2 2012 21
Dong-A Pharmaceutical Co., Ltd., H2 2012 22
Maxygen, Inc., H2 2012 23
Teva Pharmaceutical Industries Limited, H2 2012 24
Sandoz Inc., H2 2012 25
Zosano Pharma, Inc., H2 2012 26
LTT Bio-Pharma Co., Ltd., H2 2012 27
Cellerant Therapeutics, Inc., H2 2012 28
Med Discovery SA, H2 2012 29
Synageva BioPharma Corp., H2 2012 30
Phage Biotechnology Corporation, H2 2012 31
Inimex Pharmaceuticals, Inc., H2 2012 32
Bolder Biotechnology, Inc., H2 2012 33
Welichem Biotech Inc., H2 2012 34
USV Limited., H2 2012 35
Pfenex Inc., H2 2012 36
Eurofarma, H2 2012 37
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 43
Chemotherapy Induced Neutropenia Therapeutics - Drug Profile Updates 75
Chemotherapy Induced Neutropenia Therapeutics - Discontinued Products 79
Chemotherapy Induced Neutropenia Therapeutics - Dormant Products 80

List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2012 10
Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Route of Administration, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Molecule Type, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 43

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Chronic Lymphocytic Leukemia (CLL) Treatment Market worth $3.3 billion by 2018
  • New Entrants to Boost Chronic Lymphocytic Leukemia Treatment Market Value to $3.3 Billion by 2018, says GlobalData. The introduction of several new drugs will accelerate growth in the Chronic Lymphocytic Leukemia (CLL) treatment market, from $1.4 billion in 2013 to …

  • Global Biosimilars Market to Grow at a CAGR of 8.3%, to reach $262 billion by 2019
  • Lucrative Biosimilars Space to Erode Biologics Market from 2019, says GlobalData The increasing prevalence of biosimilars will have a noticeably negative impact on the biologics market beyond 2019, despite an initial projected Compound Annual Growth Rate (CAGR) of 8.3%, taking …

  • Saudi Pharmaceutical Market worth $5.9 billion by 2020
  • A high burden of chronic diseases, improving regulatory guidelines and the launch of new products will provide the necessary impetus for the growth of the pharmaceutical market in Saudi Arabia The Saudi pharmaceutical market is one of the largest markets …

  • Epithelial Ovarian Cancer – Pipeline Review, H2 2014
    Published: 15-Jul-2014        Price: US $2000 Onwards        Pages: 244
    Global Markets Direct's, ‘Epithelial Ovarian Cancer Pipeline Review, H2 2014', provides an overview of the Epithelial Ovarian Cancer's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press relea......
  • Brain Tumor – Pipeline Review, H2 2014
    Published: 15-Jul-2014        Price: US $2000 Onwards        Pages: 90
    Global Markets Direct's, ‘Brain Tumor Pipeline Review, H2 2014', provides an overview of the Brain Tumor's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Brain Tumor, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved ......
  • Neurofibromatoses Type II – Pipeline Review, H2 2014
    Published: 15-Jul-2014        Price: US $2000 Onwards        Pages: 39
    Global Markets Direct's, ‘Neurofibromatoses Type II Pipeline Review, H2 2014', provides an overview of the Neurofibromatoses Type II's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Neurofibromatoses Type II, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press relea......
  • Malignant Mesothelioma – Pipeline Review, H2 2014
    Published: 15-Jul-2014        Price: US $2000 Onwards        Pages: 100
    Global Markets Direct's, ‘Malignant Mesothelioma Pipeline Review, H2 2014', provides an overview of the Malignant Mesothelioma's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Malignant Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It a......
  • Anaplastic Astrocytoma – Pipeline Review, H2 2014
    Published: 15-Jul-2014        Price: US $2000 Onwards        Pages: 56
    Global Markets Direct's, ‘Anaplastic Astrocytoma Pipeline Review, H2 2014', provides an overview of the Anaplastic Astrocytoma's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Anaplastic Astrocytoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It a......
  • Global Ovarian Cancer Market 2014-2018
    Published: 13-Jun-2014        Price: US $2000 Onwards        Pages: 45
    Ovarian cancer is a condition where a malignancy forms in the ovarian tissue and is caused by uncontrollable cell growth. It is one of the major gynaecological cancers worldwide and a leading cause of death. Ovarian cancer is difficult to diagnose in the initial stages because the symptoms are similar to that of gastric disorders like bloating, abdominal discomfort, difficulty in eating in the early stage and nausea, vomiting, constipation and diarrhoea in the later stages. It is often diagnosed......
  • Global Breast Cancer Market 2014-2018
    Published: 13-Jun-2014        Price: US $3000 Onwards        Pages: 117
    Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer and other undifferentiated carcinoma. Ductal carcinoma is the form of breast cancer which starts in the lining of the milk ducts while lobular carcinoma begins in the milk glands of the breast. When breast cancer spreads fr......
  • Cancer Cytokines Therapy Pipeline Analysis
    Published: 12-Jun-2014        Price: US $1800 Onwards        Pages: 231
    Cytokines, a major group in the protein therapeutics umbrella, are known to be soluble extracellular proteins or glycoproteins which are crucial intercellular regulators, having the capacity to mobilize the cells which are engaged in innate as well as adaptive inflammatory host defenses, cell growth, differentiation, cell death, angiogenesis, and development and repair processes aimed at the restoration of homeostasis. These proteins are being used mostly for cancer patients due to their capabil......
  • Breast Cancer Therapeutics in Major Developed Markets to 2020 – Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs
    Published: 1-Jun-2014        Price: US $3500 Onwards        Pages: 106
    GBI Research, the leading business intelligence provider, has released its latest research, '‘Breast Cancer Therapeutics in Major Developed Markets to 2020 Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs'', which provides in-depth analysis of breast cancer therapeutics market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy) and Japan. The report provides an estimation of market s......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs